DPD-Deficiency:

The Hidden Risk in Chemotherapy

Understanding DPD Deficiency in Colon Cancer Treatment

Dihydropyrimidine dehydrogenase (DPD) deficiency is a rare but significant genetic condition that can impact the safety and effectiveness of certain colon cancer treatments. As a critical enzyme, DPD plays an essential role in metabolizing fluoropyrimidine-based chemotherapy drugs, such as 5-fluorouracil (5-FU) and capecitabine, which are commonly used to treat colon cancer. Understanding DPD deficiency is vital for patients and their families to ensure safe and personalized treatment plans.

What is DPD Deficiency?

DPD deficiency occurs when the body produces insufficient or dysfunctional DPD enzymes due to genetic variations in the DPYD gene. This enzyme is responsible for breaking down fluoropyrimidine drugs, which target rapidly dividing cancer cells. When DPD activity is reduced or absent, these drugs are not properly metabolized, leading to a buildup of toxic levels in the body. This can result in severe, potentially life-threatening side effects.

DPD deficiency varies in severity, ranging from partial to complete deficiency. It is estimated to affect a small percentage of the population, but its consequences can be fatal for those undergoing chemotherapy for colon cancer.

Why Awareness Matters

For patients diagnosed with colon cancer, understanding DPD deficiency empowers informed discussions with healthcare providers. If you or a loved one are preparing for chemotherapy, ask your doctor about DPD testing. This simple step could make a significant difference in ensuring treatment is both safe and effective.

For more information on DPD-Deficiency, please watch the video below or visit “Advocates For Universal DPD/DPYD Testing”